Favorable Effects of Burosumab on Fibroblast Growth Factor 23-Related Osteomalacia: A Case Report

Background: Fibroblast growth factor 23 (FGF23) decreases serum phosphate levels by inhibiting proximal tubular phosphate reabsorption and intestinal phosphate absorption by decreasing serum 1,25-dihydroxyvitamin D level, thereby regulating phosphate metabolism. Tumor-induced osteomalacia (TIO) is a...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:J Endocr Soc
Egile Nagusiak: Oe, Yuki, Kameda, Hiraku, Nomoto, Hiroshi, Sakamoto, Keita, Soyama, Takeshi, Cho, Kyu Yong, Nakamura, Akinobu, Abo, Daisuke, Kudo, Kohsuke, Atsumi, Tatsuya, Miyoshi, Hideaki
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Oxford University Press 2021
Gaiak:
Bone and Mineral Metabolism
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC8090139/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1210/jendso/bvab048.394
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak